Nausea and Vomiting: Antiemetic Pharmacotherapy
Core concept: Effective antiemetic treatment combines cause-directed evaluation, hydration support, and medication selection based on the predominant emetic mechanism (Wilhelm & Lipari, 2026).
Key clinical distinction: An agent that blocks emetic signaling is not interchangeable with a prokinetic; symptomatic response does not exclude serious underlying pathology.
Prescribing priority: Treat the cause and stabilize hydration before selecting an antiemetic. An effective antiemetic does not rule out obstruction, intracranial pathology, metabolic disturbance, or surgical disease (Wilhelm & Lipari, 2026).
Clinical Assessment Determines Whether Medication Is Appropriate
Characterize onset and duration, pregnancy possibility, exposure to new medications, recent anesthesia or chemotherapy, vertigo or motion triggers, abdominal pain/distension, stool passage, headache, and associated fever or diarrhea. Evaluate oral tolerance, urine output, orthostasis, mentation, and weight change. Medication review includes opioids, antibiotics, GLP-1 receptor agonists, cannabinoids, and potentially toxic ingestions (Wilhelm & Lipari, 2026).
Prompt evaluation is indicated for severe dehydration, altered mental status, gastrointestinal bleeding, persistent bilious or feculent emesis, peritoneal findings, marked abdominal distension, suspected obstruction, new focal neurologic signs, or concerning pregnancy symptoms. Symptomatic antiemetic treatment must not delay diagnostic evaluation or stabilization when alarm findings are present (Wilhelm & Lipari, 2026).
Match the Predominant Emetic Pathway to a Drug Class
| Clinical phenotype | Rational treatment direction | Cautions |
|---|---|---|
| Motion sickness / vestibular stimulation | Antihistamine H1 blockers (meclizine or dimenhydrinate) or transdermal scopolamine. | Anticholinergic burden, sedation, falls, urinary retention, angle-closure glaucoma risks; assess driving and older adult vulnerability. |
| Postoperative nausea and vomiting (PONV); otherwise cause-directed acute nausea care | 5-HT3 antagonist such as ondansetron when appropriate; consider dopamine antagonist depending on etiology and patient factors. | QT risk with electrolyte depletion or interacting agents; constipation and headache; avoid assuming all causes respond identically. |
| Gastroparesis / documented delayed gastric emptying | Consider a prokinetic such as metoclopramide rather than symptom suppression alone; specialist review when persistent. | Tardive dyskinesia warning; avoid prolonged use. Diagnose with an appropriate 4-hour gastric emptying test when indicated. |
| Chemotherapy-related nausea and vomiting (CINV) | Regimen based on chemotherapy emetogenicity, frequently combining 5-HT3, NK1, dexamethasone and sometimes olanzapine. | Use the applicable oncology regimen and check each selected drug for its product-specific interactions and adverse effects; plan for acute and delayed emesis. |
| Nausea and vomiting of pregnancy | Stepwise pregnancy-specific approach, generally nonpharmacologic measures then vitamin B6/doxylamine in suitable cases. | Assess severity and dehydration; avoid extrapolating general adult drug-risk assumptions to pregnancy. |
Antiemetic Classes and Pharmacology
| Class / examples | Target and value | High-consequence limitation |
|---|---|---|
| 5-HT3 antagonists: ondansetron, granisetron, palonosetron | Block serotonin 5-HT3 signaling at vagal afferents and central emetic pathways; useful for PONV and CINV. | QT liability differs among agents. With ondansetron, consider ECG monitoring in patients with hypokalemia, hypomagnesemia, heart failure, bradyarrhythmias, or other QT-prolonging medicines; assess constipation. |
| Dopamine D2 antagonists: metoclopramide, prochlorperazine | Act centrally at chemoreceptor trigger zone; metoclopramide also enhances gastric motility. | Assess extrapyramidal reactions and sedation; metoclopramide has a boxed warning for tardive dyskinesia. Check additional QT and interaction concerns against each drug’s own label. |
| Phenothiazine antihistamine: promethazine | H1 and antidopaminergic activity useful in selected nausea phenotypes. | Sedation, anticholinergic effects; severe tissue injury with injectable promethazine; contraindicated under 2 years. |
| Anticholinergics and H1 blockers: scopolamine, meclizine | Blunt vestibular input; best for motion-triggered symptoms. | Anticholinergic effects and sedation may limit use; assess contraindications and age-related vulnerability using the selected product label. |
| NK1 antagonists: aprepitant and related agents | Block substance P/NK1 signaling; CINV prevention as part of combination regimens. | Complex CYP3A4 drug interactions and regimen-specific dosing. |
| Glucocorticoids and olanzapine | Dexamethasone is a common CINV/PONV adjunct; olanzapine adds multireceptor coverage for selected CINV regimens. | Dexamethasone and olanzapine have different systemic adverse-effect and interaction profiles; confirm patient-specific glucose, psychiatric, sedation, and metabolic risks before use. |
Injectable promethazine is a route-specific safety hazard. The FDA recommends deep intramuscular administration in preference to intravenous delivery. When IV administration is unavoidable, follow the product-specific dilution and infusion protocol through an appropriate large vein; undiluted IV injection can cause devastating tissue injury (U.S. Food and Drug Administration, 2023).
Representative Dosing and Label Distinctions
Avoid copying an oncology premedication regimen into outpatient treatment of an acute illness. Dose, route, and timing vary considerably by indication. The following are illustrative adult considerations; full regimen verification remains necessary before prescribing (Bryant Ranch Prepack, 2025, 2026; PAI Pharma, 2024; Wilhelm & Lipari, 2026).
| Agent | Typical adult context | Safety qualification |
|---|---|---|
| Ondansetron | Ondansetron dosing is indication-, formulation-, and route-specific; the labeled adult PONV IV regimen is 4 mg once. Verify the applicable product instructions before repeat dosing. | The FDA label provides specific CINV and PONV schedules, not a universal general-nausea schedule. In severe hepatic impairment (Child-Pugh score 10 or greater), total daily dose must not exceed 8 mg. |
| Metoclopramide | Selected gastroparesis regimens are typically given before meals, with dose based on renal function and indication. | Use the exact label for dose/interval. Avoid treatment longer than 12 weeks except rare justified situations; assess EPS and mood symptoms. |
| Scopolamine transdermal | One patch is typically placed behind the ear before motion exposure and replaced according to product instructions. | Onset requires planning; avoid assuming immediate rescue effect. Inspect anticholinergic risk. |
| Prochlorperazine | Common adult oral formulations may be prescribed in divided doses for severe nausea or vomiting. | Check exact strength/route and concurrent QT/EPS or sedative agents rather than extrapolating across routes. |
Prescribing-label source note: Consult the indication-specific U.S. product labels cited in the references (Bryant Ranch Prepack, 2025, 2026; Preferred Pharmaceuticals Inc., 2026; Teva Pharmaceuticals USA, Inc., 2026); verify the current formulation, dose, warnings and population before use.
High-Risk Selection and Dose-Adjustment Checks
| Drug | Verified prescribing distinction | Safety stop / monitor |
|---|---|---|
| Ondansetron | Labeled schedules differ across chemotherapy, radiation, and postoperative use. Severe hepatic impairment (Child-Pugh score >=10): total daily dose <=8 mg. | Concomitant apomorphine is contraindicated; avoid congenital long-QT syndrome, consider ECG if electrolytes are abnormal or other QT drugs are used; watch for ileus. |
| Metoclopramide | Adult diabetic gastroparesis label: 10 mg orally 30 minutes before meals and at bedtime (maximum 40 mg/day); typical course 2–8 weeks; avoid >12 weeks. | Prior tardive dyskinesia/dystonia, epilepsy, pheochromocytoma and mechanical obstruction are contraindications. Reduce dose with CrCl <60 mL/min, moderate/severe hepatic impairment or strong CYP2D6 inhibitors. |
| Scopolamine patch | One patch behind the ear at least four hours before motion sickness; PONV patch evening before surgery, based on product directions. | Contraindicated in angle-closure glaucoma; assess urinary retention, cognitive effects, heat exposure and patch removal instructions. |
| Promethazine injection | Deep intramuscular administration is preferred. If intravenous administration is unavoidable, dilute to 1 mg/mL or less and infuse through a catheter in a large vein according to the selected product label; discontinue immediately for infusion-site pain. | IV concentrations above 1 mg/mL, intra-arterial injection, and subcutaneous injection are contraindicated. Severe tissue injury, including gangrene, is possible. Injection is contraindicated in children younger than 2 years because of potentially fatal respiratory depression. |
The regimens above are indication-specific exemplars, not a generic antiemetic order set. A patient with CKD and diabetes receiving multiple centrally active medications may require a lower metoclopramide dose or a different plan, even when a prokinetic is indicated. Do not add ondansetron without assessing QT risk when vomiting has caused significant potassium or magnesium depletion (Bryant Ranch Prepack, 2025, 2026; Preferred Pharmaceuticals Inc., 2026; Teva Pharmaceuticals USA, Inc., 2026; U.S. Food and Drug Administration, 2023).
Gastroparesis Is Not Synonymous With Generic Nausea
The 2025 AGA guideline favors a 4-hour rather than a 2-hour gastric emptying study in appropriate suspected gastroparesis. After evaluation of mechanical obstruction and mimics, metoclopramide or erythromycin may be considered first-line pharmacologic choices based on conditional recommendations. Routine first-line domperidone, prucalopride, aprepitant, and other agents are not recommended. Erythromycin is a prokinetic by motilin receptor agonism but carries tachyphylaxis, QT, CYP3A interaction, and antimicrobial-resistance considerations (Staller et al., 2025).
Metoclopramide risk rises with cumulative exposure. Stop and reassess at any abnormal involuntary movements; monitor for restlessness, mood changes, and sedation. Do not pair multiple dopamine antagonists casually (PAI Pharma, 2024).
Initial and Ongoing Monitoring
- Correct volume depletion and electrolyte abnormalities when clinically indicated. Persistently vomiting patients may require intravenous fluids, laboratory assessment, and observation.
- Define success as adequate oral intake, improved symptom burden, patient function, and control of the precipitating condition, not merely absence of emesis immediately after medication.
- Reconcile QT-prolonging medications; consider an electrocardiogram in patients with electrolyte abnormalities, heart failure, bradyarrhythmias, or concurrent QT-active drugs receiving ondansetron.
- At follow-up, ask about adverse neurologic effects, falls, excessive sedation, constipation, and new/worsening abdominal symptoms. Failure should trigger reconsideration of diagnosis rather than serial additions of antiemetics.
- Pregnancy, pediatrics, chemotherapy, and postoperative care each require indication-specific protocols and drug-label age/dosing verification.
Select Prophylaxis Versus Rescue by the Emetic Setting
Prevention and rescue are different clinical questions. For adults with PONV risk factors, current consensus favors multimodal prophylaxis and risk reduction rather than relying on one antiemetic. Evaluate established postoperative emesis for hypotension, opioids, dehydration, ileus, and other postoperative complications. When prophylaxis fails, choose rescue therapy from a different pharmacologic class. If no alternative is available and more than six hours have elapsed, another short-acting 5-HT3 antagonist or butyrophenone dose may be considered; do not routinely redose long-acting aprepitant, fosaprepitant, or palonosetron in recovery. Transdermal scopolamine is not suitable for immediate rescue because of delayed onset (Gan et al., 2026; Wilhelm & Lipari, 2026).
Chemotherapy-induced nausea and vomiting (CINV) is classified by the regimen’s emetogenic potential and by acute, delayed, or breakthrough timing; anticipatory symptoms are assessed separately in oncology care. For highly emetogenic chemotherapy, guideline-based prophylaxis commonly combines a 5-HT3 antagonist, NK1 antagonist, dexamethasone and olanzapine; this is a coordinated oncology protocol, not a regimen to copy for routine gastroenteritis. Document dexamethasone interactions, glucose burden, olanzapine sedation, and NK1-related CYP interactions. Breakthrough CINV requires reassessment of the prophylaxis regimen and a rescue strategy; MASCC/ESMO supports considering olanzapine when it was not used for primary prophylaxis (Herrstedt et al., 2024).
Pregnancy-Related Symptoms: Assess Severity Before Escalation
For nausea and vomiting of pregnancy, distinguish typical symptoms from hyperemesis with inadequate intake, weight loss, dehydration or electrolyte abnormalities. Pyridoxine with or without doxylamine is an established early option after individualized assessment. Further treatment requires maternal–fetal risk–benefit evaluation; ACOG discusses limited or conflicting fetal-safety evidence for ondansetron rather than an absolute contraindication. Patients admitted with persistent vomiting or severely reduced intake should receive thiamine supplementation, particularly before dextrose-containing fluids or parenteral nutrition, to reduce Wernicke encephalopathy risk. Assess for other obstetric, surgical and neurologic causes when the clinical presentation is atypical (American College of Obstetricians and Gynecologists, 2020; Nelson-Piercy et al., 2024; Wilhelm & Lipari, 2026).
Source correction: The 2025 erratum to the RCOG hyperemesis guideline states that intravenous prochlorperazine instructions in its appendices were erroneous; the 2026 erratum corrects the infusion time of a specific potassium-containing intravenous fluid regimen. These corrections concern that guideline’s pathway and must not be generalized into universal U.S. prescribing restrictions. Follow current local obstetric protocols and agent-specific labeling (“Correction to the Management,” 2025, 2026).
Gastroparesis: Establish Delayed Emptying and Target the Motility Problem
Suspected gastroparesis requires exclusion of mechanical obstruction and confirmation of delayed emptying, preferably with four-hour gastric emptying testing rather than a two-hour study. Review hyperglycemia, GLP-1 receptor agonist exposure, opioids and other medications that slow transit. The 2025 AGA guideline conditionally supports metoclopramide and erythromycin for treatment; erythromycin is a prokinetic via motilin receptors and may lose effect with continued use. Domperidone and prucalopride are not recommended as routine first-line choices, and U.S. domperidone access is restricted. Review neurologic adverse effects, QT, CYP interactions, renal function and the time-limited metoclopramide label before prescribing (Staller et al., 2025).
Rescue and Nonresponse: Do Not Mask a Deteriorating Diagnosis
Content last reviewed:
After a monitored antiemetic trial, reassess oral intake, vital signs, urine output, glucose, electrolytes, abdominal examination and disease-specific symptom targets. Persistent emesis with distension, obstipation or peritoneal signs warrants obstruction evaluation; hematemesis or severe pain warrants urgent work-up. Correct dehydration and potassium/magnesium abnormalities before stacking QT-prolonging drugs. If symptoms recur despite antiemetics, investigate the underlying etiology rather than merely escalating sedation (Wilhelm & Lipari, 2026).
Decision pathway: Setting
| Setting | Clinical strategy | Response and failure discriminator |
|---|---|---|
| Vestibular/motion-related | Antihistamine or antimuscarinic prophylaxis when appropriate; scopolamine is preventive, not immediate rescue. | Anticholinergic burden, glaucoma risk and sedation matter; reconsider diagnosis if neurologic deficits. |
| PONV | General multimodal prophylaxis for at-risk adults; add risk reduction strategies and switch pharmacologic class for breakthrough symptoms. | Assess postoperative complications and prior prophylaxis. Repeat a short-acting 5-HT3 antagonist or butyrophenone only in appropriate circumstances after six hours when alternatives are unavailable; avoid recovery-room redosing of long-acting agents. |
| Highly emetogenic chemotherapy | Protocolized multiday NK1 + 5-HT3 + dexamethasone + olanzapine approach. | Distinguish delayed versus breakthrough CINV and drug interactions. |
| Pregnancy | Nonpharmacologic strategies followed by pyridoxine ± doxylamine; escalate with obstetric input. | Assess hyperemesis, weight loss, dehydration and thiamine deficit. |
| Confirmed gastroparesis | Dietary changes and select prokinetic, usually time-limited metoclopramide or specialist-guided erythromycin. | Evaluate neurologic/QT risks and failure of adequate treatment; consider specialist evaluation. |
| Acute vomiting with red flags | Resuscitation and diagnosis first, targeted symptom control second. | Obstruction, bleeding, DKA, infection, neurologic cause or surgical abdomen take priority. |
Applied Clinical Case and Prescribing Rationale
Scenario: A 68-year-old with diabetes and CKD reports vomiting after meals, 8-lb weight loss and repeated ondansetron prescriptions. A recently started GLP-1 agonist is on the medication list. How should prescribing change?
Reasoned response: Assess hydration, electrolyte abnormalities and alarm features, review medication effects and exclude obstruction before labeling symptoms gastroparesis. If delayed gastric emptying is confirmed, use the indication-specific pathway and renal-adjusted, time-limited prokinetic strategy rather than indefinite ondansetron. Examine QT and neurologic risks and coordinate glycemic therapy. A 4-hour gastric emptying study, not an empiric response to metoclopramide, establishes delayed emptying (Staller et al., 2025).
Lactation: Separate Evidence Review
LactMed reports low ondansetron transfer to milk after postpartum IV dosing, without observed adverse infant effects in the available small studies; its assessment does not establish safety for every outpatient regimen. Metoclopramide reaches breast milk variably, may affect infant exposure, and can worsen maternal depression. It should not be used routinely to enhance milk supply. Select therapy according to the actual indication, maternal history and infant context (National Institute of Child Health and Human Development, 2025, 2026).
High-Yield Distinctions
High-yield point
A patient with recurrent vomiting, diabetes, and suspected delayed gastric emptying needs medication and glucose review and appropriate diagnostic testing before prolonged prokinetic therapy. A patient with motion-triggered nausea and no concerning findings is more likely to benefit from vestibular-directed H1 or antimuscarinic therapy. The same “antiemetic of choice” is not suitable for both clinical problems (Staller et al., 2025; Wilhelm & Lipari, 2026).
Key clinical distinction: 5-HT3 antagonism primarily blocks emesis signaling; prokinetics target disordered motility. Selecting a drug without defining the syndrome can suppress symptoms while leaving disease untreated.
Related YourDNP Resources
Pharmacology learning hub | GERD Pharmacotherapy | Acute Diarrhea
Content last reviewed:
References
American College of Obstetricians and Gynecologists. (2020, May). Morning sickness: Nausea and vomiting of pregnancy. https://www.acog.org/womens-health/faqs/morning-sickness-nausea-and-vomiting-of-pregnancy
Bryant Ranch Prepack. (2025, November 18). Scopolamine transdermal system [U.S. prescribing information; current online label]. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd031a59-6b8c-49b1-9b4d-e7a7b75e3801
Bryant Ranch Prepack. (2026, May 4). Ondansetron orally disintegrating tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83821ad-822e-47dc-8108-612312cf3a16
Correction to “The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-Top Guideline No. 69).” (2025). BJOG: An International Journal of Obstetrics & Gynaecology, 132(10), 1541. https://doi.org/10.1111/1471-0528.18258
Correction to “The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-Top Guideline No. 69).” (2026). BJOG: An International Journal of Obstetrics & Gynaecology, 133(9), 1823. https://doi.org/10.1111/1471-0528.70298
Gan, T. J., Jin, Z., Ayad, S., Belani, K. G., Habib, A. S., Meyer, T. A., Urman, R. D., Andrew, B. Y., Bergese, S. D., Chung, F., Diemunsch, P., Kovac, A. L., Candiotti, K., Englesakis, M., Grant, M. C., Hedrick, T. L., Huang, H., Kranke, P., Lloyd, S. J.-A., . . . Stever, J. (2026). Fifth consensus guidelines for the management of postoperative nausea and vomiting: Executive summary. Anesthesia & Analgesia, 143(3), 497–513. https://doi.org/10.1213/ANE.0000000000007816
Herrstedt, J., Celio, L., Hesketh, P. J., Zhang, L., Navari, R., Chan, A., Saito, M., Chow, R., & Aapro, M. (2024). 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer, 32(1), Article 47. https://doi.org/10.1007/s00520-023-08221-4
National Institute of Child Health and Human Development. (2025, June 15). Ondansetron. In Drugs and Lactation Database (LactMed). National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK500798/
National Institute of Child Health and Human Development. (2026, February 15). Metoclopramide. In Drugs and Lactation Database (LactMed). National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501352/
Nelson-Piercy, C., Dean, C., Shehmar, M., Gadsby, R., O’Hara, M., Hodson, K., & Nana, M. (2024). The management of nausea and vomiting in pregnancy and hyperemesis gravidarum (Green-top Guideline No. 69). BJOG: An International Journal of Obstetrics & Gynaecology, 131(7), e1–e30. https://doi.org/10.1111/1471-0528.17739
PAI Pharma. (2024, November 13). Metoclopramide hydrochloride [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cc8ca5b-8b71-4c77-a181-9ce154597b9a
Preferred Pharmaceuticals Inc. (2026, June 11). Ondansetron orally disintegrating tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e87a5803-e872-43f7-8a15-79aa236e8c07
Staller, K., Parkman, H. P., Greer, K. B., Leiman, D. A., Zhou, M. J., Singh, S., Camilleri, M., & Altayar, O. (2025). AGA clinical practice guideline on management of gastroparesis. Gastroenterology, 169(5), 828–861. https://doi.org/10.1053/j.gastro.2025.08.004
Teva Pharmaceuticals USA, Inc. (2026, March 31). Metoclopramide tablets [U.S. prescribing information; current online label]. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e15905e0-e0f6-4c8b-ac19-59724d6c4bf0
U.S. Food and Drug Administration. (2023, December 27). FDA requires updates to labeling for promethazine hydrochloride injection products. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products
Wilhelm, S. M., & Lipari, M. (2026). Nausea and vomiting. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 21). McGraw Hill.